Varenicline Tablet, Film Coated
Product Images NDC 31722-679

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Varenicline (NDC 31722-679). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Varenicline05mgand1mgcarton (Varenicline05mgand1mgcarton)

Varenicline Tablets Starting Month Box packaging label from Camber Pharmaceuticals, Inc., containing a 4-week supply with 11 tablets of 0.5 mg for the first week and 42 tablets of 1 mg for the following 3 weeks. The label includes directions to use the Starting Week (green) blister card first, the NDC 31722-690-31 code, and pharmacist dispensing instructions, with storage and contact information.*

FDA Label Image

Varenicline05mgcontainerlabel (Varenicline05mgcontainerlabel)

Varenicline 0.5 mg film-coated tablets packaging label from Camber Pharmaceuticals, Inc. The label indicates 56 tablets in the container and includes storage instructions, dosage reference, and a pharmacist warning to dispense a Medication Guide. Manufactured by Hetero Labs Limited in India, with a US contact number and barcode present.*

FDA Label Image

Varenicline05mgfoil (Varenicline05mgfoil)

Varenicline Tablets Starting Pack carton by Camber Pharmaceuticals, Inc. displays directions for use and a blister pack layout with color distinctions for different treatment weeks. It includes 0.5 mg tablets (green section) for 11 days and 1 mg tablets (blue section) for 42 days, with clear peeling instructions for blister cards inside the packaging.*

FDA Label Image

Varenicline1mgcarton (Varenicline1mgcarton)

Packaging label for Varenicline Tablets Continuing Month Box by Camber Pharmaceuticals, Inc. Contains 56 film-coated oral tablets at a 1 mg strength for 4 continuing weeks. The label includes NDC 31722-679-31, pharmacist dispensing instructions, and manufacturing details by Hetero Labs Limited, India. The box is white with blue stripes and red text highlights.*

FDA Label Image

Varenicline1mgcontainerlabel (Varenicline1mgcontainerlabel)

Varenicline Tablets 1 mg film-coated oral tablets label from Camber Pharmaceuticals, Inc. The label indicates a package of 56 tablets, prescription only, with storage instructions and a medication guide website. It features the NDC 31722-679-56 and contact information for the manufacturer in Piscataway, NJ.*

FDA Label Image

Varenicline1mgfoil (Varenicline1mgfoil)

Blister card packaging label for Varenicline Tablets, 1 mg strength, film-coated oral tablets by Camber Pharmaceuticals, Inc. The label indicates a continuing pack containing 4 weeks (56 tablets total) with dosing instructions for each day. The card is blue with clear markings for morning and evening doses and peel-back tabs for each tablet dose. Includes NDC 31722-679-31 and pharmacist dispensing instructions.*

FDA Label Image

Vareniclinecamberlogo (Vareniclinecamberlogo)

FDA Label Image

Vareniclinefigure1 (Vareniclinefigure1)

A bar graph comparing the effects of Varenicline 0.5 mg BID, Varenicline 1.0 mg BID, Varenicline Flexible, Varenicline 1.0 mg BID, Bupropion SR 150 mg BID, and Placebo across multiple studies labeled Study 2 to Study 5. The vertical axis shows percentages ranging from 0% to 60%, with bars representing different treatment groups within each study.*

FDA Label Image

Vareniclinefigure2 (Vareniclinefigure2)

A bar graph comparing the percentage outcomes of different treatments involving Varenicline (0.5 mg BID and 1.0 mg BID) against placebo and other treatments (Bupropion SR 150 mg BID) across five studies. The graph displays grouped bars for each study, showing varying response levels with error bars indicating variability.*

FDA Label Image

Vareniclinefigure3 (Vareniclinefigure3)

A line graph comparing the percentage of continuous abstinent individuals over nontreatment follow-up weeks between Varenicline 1.0 mg BID and placebo groups. The x-axis represents weeks of follow-up, and the y-axis shows the percentage abstinent, with both groups showing declining abstinence over time, Varenicline consistently higher than placebo.*

FDA Label Image

Vareniclinestructure (Vareniclinestructure)

Chemical structure of Varenicline tartrate, the active ingredient in Varenicline tablets. The image shows the molecular structure with ring systems and functional groups characteristic of Varenicline tartrate.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.